Hepatitis Treatments
Find Hepatitis Treatments
Sofosbuvir
What is Epclusa (Sofosbuvir)?
Approved To Treat
Related Clinical Trials
Summary: The goal of this non-randomised, quasi-experimental, prospective comparative trial is to trial simplified care pathways for hepatitis C testing and treatment for people who inject drugs in Armenia, Georgia, and Tanzania. The main questions it aims to answer are: 1. What is the feasibility of implementing a hepatitis C simplified care and same-day treatment care model in community and harm reductio...
Summary: Up to 650,000 people in Brazil are living with chronic hepatitis c virus (HCV) infection. Hepatitis C is a silent disease, and up to 20% of cases can progress to liver cirrhosis and its complications. Rapid tests for diagnosis of HCV infection and non-invasive methods for detecting liver cirrhosis are available in the Brazilian Public Health System. Additionally, safe and highly effective drugs (d...
Summary: This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
Related Latest Advances
Brand Information
- without cirrhosis or with compensated cirrhosis
- with decompensated cirrhosis for use in combination with ribavirin.
- 400 mg/100 mg Tablets: pink, diamond-shaped, film-coated tablet debossed with "GSI" on one side and "7916" on the other side. Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir.
- 200 mg/50 mg Tablets: pink, oval-shaped, film-coated tablet debossed with "GSI" on one side and "S/V" on the other side. Each tablet contains 200 mg of sofosbuvir and 50 mg of velpatasvir.
- 200 mg/50 mg Oral Pellets: white to off-white, film-coated pellets in unit-dose packets. Each packet contains 200 mg of sofosbuvir and 50 mg of velpatasvir.
- 150 mg/37.5 mg Oral Pellets: white to off-white, film-coated pellets in unit-dose packets. Each packet contains 150 mg of sofosbuvir and 37.5 mg of velpatasvir.
- Serious Symptomatic Bradycardia When Coadministered with Amiodarone
- For oral use only (take by mouth with or without food).
- Pellets should be swallowed whole.
- Do not open the EPCLUSA oral pellet packet(s) until ready to use.
- For children younger than 6 years, take EPCLUSA oral pellets with food.
- EPCLUSA oral pellets are white to off-white pellets supplied as single-use packets in cartons. Each carton contains 28 packets.
- Do not use EPCLUSA oral pellets if the carton tamper-evident seal or the packet has been opened or damaged.
- Daily EPCLUSA oral pellet packet(s), as prescribed by your healthcare provider
- Scissors (optional)
- One or more spoonfuls of non-acidic soft food such as pudding, chocolate syrup, or ice cream
- Bowl
- Spoon
- If taking EPCLUSA oral pellets with food, carefully pour the entire contents of the prescribed number of EPCLUSA oral pellet packet(s) onto the food in the bowl and gently mix with a spoon (see Figure F). Take the EPCLUSA oral pellets and food mixture within 15 minutes without chewing to avoid a bitter taste.
- If taking EPCLUSA oral pellets by mouth, pour the entire contents of the prescribed number of EPCLUSA oral pellet packet(s) directly in the mouth and swallow without chewing to avoid a bitter taste (see Figure G). Water may be taken after swallowing the pellets, if needed.
- Store EPCLUSA pellets below 86°F (30°C).
- Keep EPCLUSA oral pellets and all medicines out of the reach of children.
- Throw away (dispose of) any unused portion. Do not store and reuse any leftover EPCLUSA oral pellets or EPCLUSA mixture (oral pellets mixed with food).






